lifestyle.side.cr

Author: Artios Pharma

Artios Further Expands Leadership Team to Advance Oncology Pipeline and Accelerate Regulatory Execution

May 4, 2026
Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer

March 2, 2026
Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer

February 23, 2026
Artios Strengthens Leadership Team to Accelerate Late-Stage Development of Potential First-in-Class Oncology Pipeline

February 16, 2026